The Trial of Org 10172 of Acute Stroke Treatment pada Era Pandemi COVID-19

Auliya Putri Ayu, Lisda Amalia

Abstract


Latar Belakang dan Tujuan: Klasifikasi The Trial of Org 10172 of Acute Stroke Treatment (TOAST) diperkenalkan untuk mengklasifikasikan stroke iskemik berdasarkan mekanisme etiologi potensial. Tujuan dari penelitian ini adalah untuk menilai karakteristik pasien stroke iskemik akut berdasarkan klasifikasi TOAST pada era pandemi COVID-19.
Subjek dan Metode: Penelitian ini adalah studi deskriptif dengan metode potong lintang, yang menggunakan data catatan medis pasien stroke iskemik akut yang dirawat di Departemen Neurologi Rumah Sakit Hasan Sadikin pada tahun 2021.
Hasil: Sebanyak 136 pasien stroke iskemik akut terlibat pada studi ini. Large-artery atherosclerosis (LAA) adalah subtipe stroke yang paling umum (30,1%) dan hipertensi merupakan faktor risiko terbanyak (97%). Faktor risiko hiperkoagulasi ditemukan sebanyak 79% pada klasifikasi Undetermined etiology dan 100% pada klasifikasi Other etiology.
Simpulan: Pada era pandemi COVID-19 ditemukan hiperkoagulasi sebagai faktor risiko dominan pada klasifikasi Undetermined etiology dan Other etiology. Mekanisme koagulopati pada COVID-19 dapat meningkatkan risiko stroke pada orang yang terinfeksi, yang memiliki faktor risiko stroke yang konvensional.

 

The Trial of Org 10172 of Acute Stroke Treatment during Pandemic Era

Abstract

Background and Objective: The Trial of Org 10172 of Acute Stroke Treatment (TOAST) classification was introduced to classify ischemic stroke based on potential etiological mechanisms. The purpose of this study was to assess the characteristics of acute ischemic stroke patients based on the TOAST classification during the COVID-19 pandemic era.
Subject and Methods: This research was a descriptive cross-sectional study from the medical records of acute ischemic stroke patients who were treated in Neurology ward of Hasan Sadikin Hospital in 2021.
Results: A total of 136 acute ischemic stroke patients were involved in this study. Large-artery atherosclerosis (LAA) was the most common stroke subtype (30.1%) and hypertension is the most common risk factor (97%). The risk factors for hypercoagulation were found to be 79% in the Undetermined etiology classification and 100% in the Other etiology classification.
Conclusion: In the COVID-19 pandemic era, hypercoagulation was found as the dominant risk factor in the Undetermined etiology and Other etiology classifications. The coagulopathy mechanism in COVID-19 could increase the risk of stroke in affected person who have conventional stroke risk factors.

 


Keywords


Era pandemi, stroke iskemik akut, TOAST

Full Text:

PDF

References


Radu RA, Terecoas EO, Bajenaru OA, Tiu C. Etiologic classification of ˘ ischemic stroke: where do we stand?. Clinical Neurology and Neurosurgery. 2017; 159: 93-106. doi: https://doi.org/10.1016/j.clineuro.2017.05.019.

Centers for Disease Control and Prevention. Underlying Cause of Death, 1999–2018. CDC Online Database. Centers for Disease Control and Prevention; 2018. Accessed March 12, 2020.

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics—2022 update: A report from the American Heart Association. Circulation. 2022;145(8):e153–e639. doi: https://doi.org/10.1161/CIR.0000000000001052

Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9): 767–83. doi: https://doi.org/10.1016/S1474-4422(20)30221-0

Coupland AP, Thapar A, Qureshi MI, Jenkins H, Davies AH. The definition of stroke. J R Soc Med. 2017; 110(1): 9–12. doi: 10.1177/0141076816680121.

Simonsen SA, West AS, Heiberg AV, Wolfram F, Jennum PJ, Iversen HK. Is the TOAST Classification Suitable for Use in Personalized Medicine in Ischemic Stroke? Journal of Personalized Medicine. 2022; 12(3):496. doi: https://doi.org/10.3390/jpm12030496

Harris S, Sungkar S, Rasyid A, Kurniawan M, Mesiano T, Hidayat R. TOAST subtypes of ischemic stroke and its risk factors: a hospital-based study at Cipto Mangunkusumo Hospital, Indonesia. Stroke Research and Treatment. 2018, 1–6.

Ortega-Gutierrez S, Farooqui M, Zha A, Czap A, Sebaugh J, Desai S, et al. Decline in mild stroke presentations and intravenous thrombolysis during the COVID-19 pandemic: the Society of Vascular and Interventional Neurology Multicenter Collaboration. Clin Neurol Neurosurg. 2021;201:106436. doi: https://doi.org/10.1016/j.clineuro.2020.106436

Bahou Y, Ajour M, Jaber M. Ischemic stroke at Jordan University Hospital: a one-year hospital-based study of subtypes and risk factors.SM J Neurol and Neurosc. 2015; 1(1):1003.

Hisham NF, Bayraktutan U. Epidemiology, pathophysiology, and treatment of hypertension in ischaemic stroke patients. J Stroke Cerebrovasc Dis. 2013; 22(7): e4–e14. doi: https://doi.org /10.1016/j.jstrokecerebrovasdis.2012.05.001

Shah SP, Shrestha A, Pandey SR, Sigdel K, Sah N, Panthi S, et al. Dyslipidemia in acute non-cardioembolic ischemic stroke patients at a tertiary care centre: A descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2022;60(247):241–45. doi: https://doi.org/10.31729/jnma.7321

Yaghi S, Elkind MSV. Lipids and cerebrovascular disease. Stroke. 2015;46(11): 3322–8. doi: https://doi.org/10.1161/STROKEAHA.115.011164

Jalota A, Scarabelli TM, Saravolatz L, Bakhsh MU, Agrawal P, Jalota R, et al. Novel anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(3):247-62. doi: https://doi.org/10.1007/s10557-014-6524-y

Ramos-Araque ME, Siegler JE, Ribo M, Requena, M, López C, de Lera M, et al. Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry. BMC Neurology. 2021;21:43. doi: https://doi.org/10.1186/s12883-021-02075-1

Getu S, Tiruneh T, Andualem H, Hailemichael W, Kiros T, Belay DM, et al. Coagulopathy in SARS-CoV-2 infected patients: implication for the management of COVID 19. J Blood Med. 2021;12:635–43.

Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe?. Life Sci. 2020;256:117900. doi: https://doi.org/10.1016/j.lfs.2020.117900

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-098. https://doi.org/10.1007/s00134-020-06062-x

Kim Y, Khose S, Abdelkhaleq R, Salazar-Marioni S, Zhang G-Q and Sheth SA. Predicting in-hospital mortality using D-dimer in COVID-19 patients with acute ischemic stroke. Front Neurol. 2021;12:702927. doi: https://doi.org/10.3389/fneur.2021.702927

Bhatia R, Radhakrishna P, Komakula S, Srivastava M.VP, Vishnubhatla S, Khurana D. Stroke in coronavirus disease 2019: A systematic review. J Stroke. 2020;22(3):324–35. doi: https://doi.org/10.5853/jos.2020.02264

Mori K, Tsujita Y, Yamane T, Eguchi Y. Decreasing Plasma Fibrinogen Levels in the Intensive Care Unit Are Associated with High Mortality Rates In Patients With Sepsis-Induced Coagulopathy. Clin Appl Thromb Hemost. 2022;28:10760296221101386. doi: https://doi.org/10.1177/10760296221101386




DOI: https://doi.org/10.24244/jni.v12i2.530

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License